Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, Neuherberg/Munich, D85764, Germany.
Part Fibre Toxicol. 2009 Dec 2;6:31. doi: 10.1186/1743-8977-6-31.
Carbonaceous nanoparticles possess an emerging source of human exposure due to the massive release of combustion products and the ongoing revolution in nanotechnology. Pulmonary inflammation caused by deposited nanoparticles is central for their adverse health effects. Epidemiological studies suggest that individuals with favourable lung physiology are at lower risk for particulate matter associated respiratory diseases probably due to efficient control of inflammation and repair process. Therefore we selected a mouse strain C3H/HeJ (C3) with robust lung physiology and exposed it to moderately toxic carbon nanoparticles (CNP) to study the elicited pulmonary inflammation and its resolution.
5 mug, 20 mug and 50 mug CNP were intratracheally (i.t.) instilled in C3 mice to identify the optimal dose for subsequent time course studies. Pulmonary inflammation was assessed using histology, bronchoalveolar lavage (BAL) analysis and by a panel of 62 protein markers.
1 day after instillation of CNP, C3 mice exhibited a typical dose response, with the lowest dose (5 mug) representing the 'no effect level' as reflected by polymorphonuclear leucocyte (PMN), and BAL/lung concentrations of pro-inflammatory proteins. Histological analysis and BAL-protein concentration did not reveal any evidence of tissue injury in 20 mug CNP instilled animals. Accordingly time course assessment of the inflammatory response was performed after 3 and 7 days with this dose (20 mug). Compared to day 1, BAL PMN counts were significantly decreased at day 3 and completely returned to normal by day 7. We have identified protein markers related to the acute response and also to the time dependent response in lung and BAL. After complete resolution of PMN influx on day 7, we detected elevated concentrations of 20 markers that included IL1B, IL18, FGF2, EDN1, and VEGF in lung and/or BAL. Biological pathway analysis revealed these factors to be involved in a closely regulated molecular cascade with IL1B/IL18 as upstream and FGF2/EDN1/VEGF as downstream molecules.
Considering the role of VEGF, FGF2 and EDN1 in lung development and morphogenesis together with the lack of any evident tissue damage we suggest a protective/homeostatic machinery to be associated in lungs of stable organisms to counter the CNP challenge as a precautionary measure.
由于燃烧产物的大量释放和纳米技术的不断发展,碳质纳米颗粒成为人类暴露的新兴来源。沉积的纳米颗粒引起的肺部炎症是其不良健康影响的核心。流行病学研究表明,具有良好肺部生理功能的个体患与颗粒物相关的呼吸道疾病的风险较低,这可能是由于其对炎症和修复过程的有效控制。因此,我们选择了一种具有强大肺部生理功能的 C3H/HeJ(C3)小鼠品系,并将其暴露于中等毒性的碳纳米颗粒(CNP)中,以研究引发的肺部炎症及其消退。
将 5μg、20μg 和 50μg 的 CNP 通过气管内(i.t.)滴注到 C3 小鼠体内,以确定后续时间过程研究的最佳剂量。通过组织学、支气管肺泡灌洗(BAL)分析和 62 种蛋白质标志物的组合评估肺部炎症。
在 CNP 滴注后 1 天,C3 小鼠表现出典型的剂量反应,最低剂量(5μg)代表多形核白细胞(PMN)和促炎蛋白的 BAL/肺浓度的“无效应水平”。组织学分析和 BAL 蛋白浓度在 20μg CNP 滴注动物中未显示任何组织损伤的证据。因此,在该剂量(20μg)下,在 3 天和 7 天后进行了炎症反应的时间过程评估。与第 1 天相比,第 3 天 BAL 中性粒细胞计数显著降低,第 7 天完全恢复正常。我们已经确定了与急性反应以及肺和 BAL 中时间依赖性反应相关的蛋白质标志物。在第 7 天 PMN 流入完全消退后,我们在肺和/或 BAL 中检测到 20 种标志物的浓度升高,其中包括 IL1B、IL18、FGF2、EDN1 和 VEGF。生物途径分析表明,这些因素参与了一个紧密调控的分子级联反应,其中 IL1B/IL18 作为上游,FGF2/EDN1/VEGF 作为下游分子。
考虑到 VEGF、FGF2 和 EDN1 在肺发育和形态发生中的作用以及没有任何明显的组织损伤,我们建议在稳定生物体内的肺部存在一种保护/动态平衡机制,以作为一种预防措施来应对 CNP 挑战。